Stop the jab - Johnson & Johnson vaccine rollout paused
Klavs Valters
14/4/2021
•
0 min read
Share this post
Copy URL
805,734,252 – that’s how many doses of the COVID-19 vaccine have been given globally so far as of the 12 th April (from 185 locations), according to Our World in Data. Israel, Bahrain and Chile are leading the way with 54.7%, 24.7% and 24.6% of the population fully vaccinated. With more and more people getting the jab across the world, the chance of side effects becomes more likely.
We have already seen the AstraZeneca vaccine being suspended for use for in few countries. Today, it was announced that the US agencies are calling to pause the Johnson & Johnson vaccine rollout after reports of extremely rare blood clot cases. Following the FDA and CDC advice, all federal sites in the US have stopped using the vaccine until further investigation.
European Union and South Africa have also confirmed that they will temporally stop the rollout of the Johnson & Johnson jab. The share price of Johnson & Johnson was down by around 1.34% following the latest news on their vaccine, trading at $159.48 per share the close. The stock is up by 1.57% year-to-date.
Johnson & Johnson - YTD Chart Source: TradingView You can trade Johnson & Johnson (JNJ) and many other stocks from the ASX, NYSE, and the NASDAQ with GO Markets as a Share CFD. Click here for more information. Trading Derivatives carries a high level of risk.
By
Klavs Valters
Account Manager, GO Markets London.
The information provided is of general nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information provided, you should consider whether the information is suitable for you and your personal circumstances and if necessary, seek appropriate professional advice. All opinions, conclusions, forecasts or recommendations are reasonably held at the time of compilation but are subject to change without notice. Past performance is not an indication of future performance. Go Markets Pty Ltd, ABN 85 081 864 039, AFSL 254963 is a CFD issuer, and trading carries significant risks and is not suitable for everyone. You do not own or have any interest in the rights to the underlying assets. You should consider the appropriateness by reviewing our TMD, FSG, PDS and other CFD legal documents to ensure you understand the risks before you invest in CFDs.
Tuesday, 12 May 2026, at roughly 7:30 pm AEST, Treasurer Jim Chalmers will stand up in Canberra and deliver the 2026-27 Federal Budget. According to Budget.gov.au, that is when the Budget is officially released, with the Budget papers going live online at the same time.
市場對頂尖製程晶圓及先進封裝(Advanced Packaging)的瘋狂胃納,其增長速度早已遠遠超越了全球供應鏈所能溫和承受的極限。這種極端的供需失衡,正強行逼迫各大 AI 龍頭大廠積極評估「第二供貨源(Second-source)」—— 呢點要稍為校準:這並不代表大廠們正在拋棄台積電,而是他們在實戰中迫切需要多一條通往大規模量產的備用防線。
支撐英特爾未來繼續狂飆的牛市邏輯非常直觀:**全球 AI 算力需求依舊極其瘋狂**,台積電的產能死鎖在短期內根本無法解開,這倒逼跨國科技巨頭必須不計代價尋求具備實質技術公信力的第二代工防線。如果英特爾能成功將目前的秘密測試與意向訂單逐步轉化為實質性的商業產出,全球長線資金將繼續為其晶圓代工戰略瘋狂計價。
最後,不容忽視的是更宏觀的 **AI 資本開支大週期**。一旦 Google、微軟、亞馬遜和 Meta 等超大規模雲端商(Hyperscalers)未來在龐大的基礎設施投入上放緩步伐、或是 AI 商業化變現的投資回報率(ROI)不如預期,成個半導體板塊都將迎來泥沙俱下的結構性大回撤,無論英特爾 Foundry 的製程進展得幾咁完美也無法獨善其身。
綜上所述,主導接下來外匯與股票交叉盤生死的黃金變數包括:輝達會否發出實質生產訂單、18A 工藝的最新良率進展、英特爾代工業務的虧損限度、台積電先進封裝擴產速度,以及北美雲端巨頭們的 AI 資本開支是否依舊強悍。